For patients whose conditions have not responded to conventional care, Brightiva may produce meaningful results where other approaches have fallen short. For prescribers looking to expand what they can offer, it fits within a standard outpatient setting without additional infrastructure or operational burden.
Brightiva is administered as a small tablet that dissolves in the mouth in your provider’s office, under direct clinical supervision. Vital signs are monitored before and after each session. Unlike IV ketamine, which requires a specialized infusion suite and carries a significantly higher cost per session, Brightiva is designed to be accessible for both the practices that offer it and the patients who need it.
The treatment environment matters. Providers are encouraged to create a calm, private setting with comfortable seating, dimmed lighting, and soft background music. Patients who feel at ease tend to respond better. You will want to silence your phone and allow yourself to be fully present for the session.
Treatment follows a structured protocol developed and refined by Dr. Hebig. The full protocol is available to licensed prescribers inside the Brightiva physician portal. Based on Dr. Hebig’s clinical experience, many patients report meaningful improvement within the first two weeks. Some have experienced relief after a single session. Your provider will determine the appropriate treatment schedule and whether a maintenance phase is right for you.
Based on Dr. Hebig’s clinical experience, Brightiva has produced meaningful relief for patients living with treatment-resistant depression, anxiety, PTSD, bipolar depression, OCD, substance use disorders, chronic fatigue, and fibromyalgia.
Your provider will determine whether Brightiva is clinically appropriate for your individual situation and will conduct a full clinical assessment before recommending treatment. Brightiva is not appropriate for patients with a history of mania, hypomania, psychosis, poorly controlled high blood pressure, pregnancy, or certain other conditions.
Brightiva is available in multiple dose strengths, allowing providers to tailor treatment to each patient’s needs and adjust as they progress. All formulations are compounded by certified partner pharmacies and prepared specifically for each individual patient, then shipped directly to the treating provider’s office.
Brightiva is administered only within a supervised clinical setting and is not available for home use. For patients with specific contraindications to one or more components of the formulation, an alternative ketamine-only formulation is also available through the Network.
*Brightiva is a compounded formulation that has not been approved by the FDA for treatment of any medical or psychiatric indications.